We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Existing AERS System Still Has Value, FDA Safety Advisers Say
Existing AERS System Still Has Value, FDA Safety Advisers Say
May 20, 2005
The FDA’s current passive system for monitoring adverse drug reactions shouldn’t be abandoned, according to FDA drug-safety advisers, who last week urged the agency to improve the system by creating regional reporting centers, focusing resources on more promising data sets and requiring mandatory reporting by physicians.